Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | TACR2 | P21452 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28685167 | 0.84 | LMNA (0.55) | LMNAPOLBTSHRALDH1A1KDM4E | |
| SCHEMBL87864 | 0.83 | ALDH1A1 (0.52) | LMNATSHRCYP3A4ALDH1A1KDM4E | |
| SCHEMBL1620757 | 0.83 | LMNA (0.56) | LMNAPOLBTSHRCYP3A4ALDH1A1 | |
| SCHEMBL27620235 | 0.82 | ALDH1A1 (0.56) | LMNAPOLBTSHRCYP3A4ALDH1A1 | |
| SCHEMBL1882851 | 0.79 | LMNA (0.51) | LMNAPOLBTSHRCYP3A4ALDH1A1 | |
| SCHEMBL27341504 | 0.77 | LMNA (0.55) | LMNAPOLBTSHRCYP3A4ALDH1A1 | |
| SCHEMBL3372169 | 0.76 | ALDH1A1 (0.53) | LMNAPOLBCYP3A4ALDH1A1KDM4E | |
| SCHEMBL22836211 | 0.76 | PRKDC (0.40) | LMNAPOLBTSHRALDH1A1KDM4E | |
| SCHEMBL22836575 | 0.76 | LMNA (0.60) | LMNAPOLBTSHRCYP3A4ALDH1A1 | |
| SCHEMBL30902485 | 0.76 | LMNA (0.47) | LMNAPOLBTSHRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240654-A1 | HYDRAZIDE DERIVATIVES | CLARK RICHARD | 2010-09-23 | — | — | US | disclosed |
| US-20100240654-A1 | HYDRAZIDE DERIVATIVES | CLARK RICHARD | 2010-09-23 | — | — | US | disclosed |
| US-20100240654-A1 | HYDRAZIDE DERIVATIVES | CLARK RICHARD | 2010-09-23 | — | — | US | disclosed |
| US-20080132507-A1 | Hydrazide Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080132507-A1 | Hydrazide Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1810965-A1 | HYDRAZIDE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2007-07-25 | — | — | EP | disclosed |
| EP-1810965-A1 | HYDRAZIDE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240654-A1 | HYDRAZIDE DERIVATIVES | H1-10, H1-4, H1-3 | LMNA 1953/4885POLB 1949/4885TSHR 323/4885 |
| US-20080132507-A1 | Hydrazide Derivatives | H1-10, H1-4, H1-3 | LMNA 1953/4885POLB 1949/4885TSHR 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.